Gould Capital LLC Acquires New Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Gould Capital LLC bought a new position in Charles River Laboratories International, Inc. (NYSE:CRL) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 6,217 shares of the medical research company’s stock, valued at approximately $1,225,000.

Several other large investors have also recently bought and sold shares of the company. Tortoise Investment Management LLC raised its holdings in Charles River Laboratories International by 77.0% during the 2nd quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company’s stock valued at $27,000 after buying an additional 57 shares during the last quarter. Wolff Wiese Magana LLC purchased a new stake in shares of Charles River Laboratories International in the 3rd quarter worth about $32,000. Assetmark Inc. boosted its stake in Charles River Laboratories International by 1,153.3% during the third quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock worth $37,000 after acquiring an additional 173 shares in the last quarter. Whittier Trust Co. of Nevada Inc. grew its holdings in Charles River Laboratories International by 219.3% in the second quarter. Whittier Trust Co. of Nevada Inc. now owns 281 shares of the medical research company’s stock worth $58,000 after purchasing an additional 193 shares during the period. Finally, Covestor Ltd increased its stake in shares of Charles River Laboratories International by 40.9% during the third quarter. Covestor Ltd now owns 327 shares of the medical research company’s stock valued at $65,000 after purchasing an additional 95 shares in the last quarter. 98.91% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on CRL. UBS Group lifted their price objective on Charles River Laboratories International from $240.00 to $250.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Citigroup cut shares of Charles River Laboratories International from a “neutral” rating to a “sell” rating and dropped their price target for the stock from $215.00 to $175.00 in a research note on Tuesday, October 1st. CLSA lowered shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price objective for the company. in a research note on Monday, November 18th. Robert W. Baird dropped their target price on shares of Charles River Laboratories International from $191.00 to $190.00 and set a “neutral” rating on the stock in a research note on Friday, September 20th. Finally, Evercore ISI raised their price target on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a research report on Thursday, November 7th. Three analysts have rated the stock with a sell rating, eleven have given a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $214.38.

Insider Activity

In related news, Director Richard F. Wallman sold 6,621 shares of Charles River Laboratories International stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $216.12, for a total value of $1,430,930.52. Following the completion of the transaction, the director now owns 12,386 shares in the company, valued at approximately $2,676,862.32. This trade represents a 34.83 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 1.30% of the company’s stock.

Charles River Laboratories International Trading Up 5.2 %

Charles River Laboratories International stock opened at $201.76 on Tuesday. Charles River Laboratories International, Inc. has a 52-week low of $176.48 and a 52-week high of $275.00. The company has a market cap of $10.32 billion, a P/E ratio of 25.25, a P/E/G ratio of 4.95 and a beta of 1.38. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61. The business has a 50-day simple moving average of $194.19 and a two-hundred day simple moving average of $203.56.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, beating analysts’ consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The business had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $975.99 million. The firm’s revenue was down 1.6% on a year-over-year basis. During the same period in the prior year, the company earned $2.72 earnings per share. Analysts predict that Charles River Laboratories International, Inc. will post 10.18 EPS for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).